ACAD
48.6
-0.7
-1.42%
AEMD
9.55
-0.03
-0.31%
APRI
1.49
+0.02
+1.36%
ARNA
4.09
+0.01
+0.25%
ATEC
1.36
0.00
0.00%
CNAT
4.93
-0.09
-1.79%
CRXM
0.3
0.00
0.00%
CYTX
0.44
0.00
0.00%
DXCM
83.56
+0.15
+0.18%
GNMK
8.75
-0.08
-0.91%
HALO
23.43
-0.28
-1.18%
ILMN
217.19
-0.63
-0.29%
INNV
0.155
0.00
0.00%
INO
7.4
0.00
0.00%
ISCO
0.043
0.00
0.00%
ISIS
53.05
-1.35
-2.48%
LGND
106.86
+1.02
+0.96%
LPTN
0.275
-0.005
-1.8571%
MBVX
1.8
+0.21
+13.21%
MEIP
1.65
+0.08
+5.10%
MNOV
3.87
+0.22
+6.03%
MRTX
27.46
-1.84
-6.28%
MSTX
0.454
-0.006
-1.2609%
NBIX
50.66
-1.26
-2.43%
NUVA
54.59
+4.12
+8.16%
ONCS
6.17
-0.1
-1.59%
ONVO
3.54
+0.17
+5.04%
OREX
3.91
-0.48
-10.93%
OTIC
26.11
-1.17
-4.29%
QDEL
21.47
-0.41
-1.87%
RCPT
227.64
+0.48
+0.21%
RGLS
8.19
-0.73
-8.18%
RMD
55.92
-0.78
-1.38%
SCIE
0.02
0.00
0.00%
SPHS
0.9
-0.01
-1.1425%
SRNE
19.2
-1.21
-5.93%
TROV
8.01
-0.34
-4.07%
VICL
0.638
-0.002
-0.2656%
ZGNX
18.49
-1.65
-8.19%
ACAD
48.6
-0.7
-1.42%
AEMD
9.55
-0.03
-0.31%
APRI
1.49
+0.02
+1.36%
ARNA
4.09
+0.01
+0.25%
ATEC
1.36
0.00
0.00%
CNAT
4.93
-0.09
-1.79%
CRXM
0.3
0.00
0.00%
CYTX
0.44
0.00
0.00%
DXCM
83.56
+0.15
+0.18%
GNMK
8.75
-0.08
-0.91%
HALO
23.43
-0.28
-1.18%
ILMN
217.19
-0.63
-0.29%
INNV
0.155
0.00
0.00%
INO
7.4
0.00
0.00%
ISCO
0.043
0.00
0.00%
ISIS
53.05
-1.35
-2.48%
LGND
106.86
+1.02
+0.96%
LPTN
0.275
-0.005
-1.8571%
MBVX
1.8
+0.21
+13.21%
MEIP
1.65
+0.08
+5.10%
MNOV
3.87
+0.22
+6.03%
MRTX
27.46
-1.84
-6.28%
MSTX
0.454
-0.006
-1.2609%
NBIX
50.66
-1.26
-2.43%
NUVA
54.59
+4.12
+8.16%
ONCS
6.17
-0.1
-1.59%
ONVO
3.54
+0.17
+5.04%
OREX
3.91
-0.48
-10.93%
OTIC
26.11
-1.17
-4.29%
QDEL
21.47
-0.41
-1.87%
RCPT
227.64
+0.48
+0.21%
RGLS
8.19
-0.73
-8.18%
RMD
55.92
-0.78
-1.38%
SCIE
0.02
0.00
0.00%
SPHS
0.9
-0.01
-1.1425%
SRNE
19.2
-1.21
-5.93%
TROV
8.01
-0.34
-4.07%
VICL
0.638
-0.002
-0.2656%
ZGNX
18.49
-1.65
-8.19%
Home » Archive by Category

Xconomy

Celgene to Use Cypher Genomics’ Data Analytics in Drug Development

May 20, 2015 – 5:00 am

Under a collaboration announced today, San Diego-based Cypher Genomics said it would use its biomarker discovery service to help New Jersey’s Celgene (NASDAQ: CELG) identify key genetic variants…

[[Click headline to continue reading.]]

Celgene to Use Cypher Genomics’ Data Analytics in Drug Development

May 20, 2015 – 5:00 am

Under a collaboration announced today, San Diego-based Cypher Genomics said it would use its biomarker discovery service to help New Jersey’s Celgene (NASDAQ: CELG) identify key genetic variants…

[[Click headline to continue reading.]]

Fate Therapeutics, Riding High on Juno Deal, Raising More Cash

May 19, 2015 – 8:41 am

Taking advantage of a healthy bounce on Wall Street, San Diego’s Fate Therapeutics (NASDAQ: FATE) said Monday it plans to sell 6 million shares of its common stock through a secondary public…

[[Click headline to continue reading.]]

Fate Therapeutics, Riding High on Juno Deal, Raising More Cash

May 19, 2015 – 8:41 am

Taking advantage of a healthy bounce on Wall Street, San Diego’s Fate Therapeutics (NASDAQ: FATE) said Monday it plans to sell 6 million shares of its common stock through a secondary public…

[[Click headline to continue reading.]]

Four Tough Questions Startup CEOs Need to Ask to Scale

May 19, 2015 – 7:26 am

Mark Organ thinks very differently about how to evolve as a founder-CEO now that he’s on his second company. A decade ago, Mark co-founded customer relations management software company Eloqua. “I…

[[Click headline to continue reading.]]

Still Room For Great Guests at Napa Summit 2015—Request An Invite

May 18, 2015 – 6:43 am

“It’s like a mini-Davos.” That’s the way one leading venture capitalist describes Xconomy’s Napa Summit. And while he is perhaps a bit effusive, we do believe our annual retreat in wine country is…

[[Click headline to continue reading.]]

Talking Cure? For Cancer Immunotherapy, Still Many Rivers to Cross

May 12, 2015 – 3:30 am

Cancer is a humbling thing: Our own cells gone bad, killing us from the inside, and so often able to rebound from attack or avoid it entirely. There has been progress fighting some types of cancers,…

[[Click headline to continue reading.]]

Reflections on the “Build to Buy,” Part 2: The Applicability Problem

April 30, 2015 – 3:35 am

In a prior Xconomy post, I explored the unwritten and often hidden challenges of successfully navigating and completing a ‘build to buy’ acquisition. The fundamental issue that underlies those…

[[Click headline to continue reading.]]

Preeclampsia Test Developer Carmenta Bought For Undisclosed Sum

April 29, 2015 – 12:42 pm

Any expectant parent knows that preeclampsia—a kind of high blood pressure during pregnancy—is a dreaded possibility. It can be fatal for mother and baby, and it can be difficult to…

[[Click headline to continue reading.]]

Viking Therapeutics Set to Make Nasdaq Debut Following IPO

April 29, 2015 – 8:18 am

Viking Therapeutics (NASDAQ: VKTX) said its shares are expected to begin trading today, after the San Diego biopharmaceutical raised $24 million in its initial public offering last night by selling 3…

[[Click headline to continue reading.]]